Generic powerhouse Teva Pharmaceutical Industries ($TEVA) and Takeda said last year that they were working a deal to sell generics in Japan, a piece of the market expected to grow significantly as the government pushes off-patent drugs. Now the two have released details about how they will do that. The companies said they will shift to the new company products that include Blopress for hypertension, Takepron for peptic ulcers, and Basen for Type 2 diabetes. In a statement, they said those drugs generated sales in 2014 of ¥125 billion ($1.03 billion) in fiscal 2014. Read more from FiercePharmaAsia